Research funder · United States
Michael J. Fox Foundation for Parkinson's Research
Non-profit organization in the USA
- Grants since 2016
- 1 275
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 3 085
- Funded works, all time
- 6 716
Grants
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Preclinical Efficacy and Biomarker Development for a Clinical Stage Inhibitor of Lipid Metabolism in Parkinson’s Disease
Daniel F. Tardiff · Yumanity Therapeutics (United States)
2021 · research · Research Grant
Parkinson’s Disease Patient Report of Problems (PD-PROP) Curation
Ira Shoulson · Grey Matter Technologies Llc
2021 · research · Target Advancement Program
Use of Therapeutic Nanoparticles to Inhibit Toxic Aggregation of Alpha-Synuclein
Sally A. Frautschy · Ucla, Department Of Neurology And Medicine
2021 · research · Alpha-synuclein Seed Amplification Assay Program
Detection of Single Molecules of Alpha-synuclein in Extracellular Vesicles
David R. Walt · Harvard University
2021 · research · Research Grant Supplement
Profiling the Removal of Damaged Mitochondria in Stem Cell-Derived Brain Cells from People with Parkinson’s
Richard Wade-Martins · University of Oxford
2021 · research · Aligning Science Across Parkinson's
Reconstituting the Lost Nigrostriatal Circuitry in Parkinson’s Disease
William C. Mobley · University of California San Diego
2021 · research · Target Advancement Program
Enhancing Treatment Efficacy by Eliminating L-dopa Metabolizing Gut Bacteria
Stavros Bashiarde · Cyprus Institute of Neurology and Genetics
2021 · research · Outcome Measures
Assessing Parkinson’s at Home: Contactless Monitoring of Sleep, Motor Symptom Progression and Medication Response
Dina Katabi · Emerald Innovations, Inc.
2021 · research · Priority Biology
Developing New Therapeutic Drugs for Parkinson’s in Human Stem Cell Neurons
Richard Wade-Martins · University of Oxford
2021 · research · Fall 2021 RFP: Outcome Measures
Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids
Lara Petricca · Nd-biosciences
2021 · research · Analysis of Patient-Reported Outcomes from Fox Insight
Exploring Environmental and Genetic Mediators of Progression in Parkinson’s Disease
Ethan G. Brown · University of California, San Francisco
2021 · research · Fall 2021 RFP: Expanding Biological Understanding of PD
Using Human iPSC to Explore the Role of the STING Pathway in Parkinson's Disease
William S. James · University of Oxford
2021 · research · Diversity, Equity and Inclusivity in Parkinson's research
Study of Cognitive Differences in a South Asian Population with Parkinson’s Disease
Alastair Noyce · Queen Mary University of London
2021 · research · Research Grant Supplement
The Role of LRRK2 in the Accumulation and Spread of Tau Protein
Michael Henderson · Van Andel Institute
2021 · research · Environmental Risk Factors
Exposure to Ambient Air Pollution and Risk of Parkinson’s Disease
Anna-Maija Tolppanen · University of Eastern Finland
2021 · research · Target Advancement Program
Targeting the Neurovascular Unit to Prevent Dissemination and Progression of Parkinson’s Disease
Francesca Cicchetti · Université Laval
2021 · research · Therapeutic Pipeline Program
RNA Targeting Small Molecules as Therapeutics for Parkinson's
Mary Maral Mouradian · William Dow Lovett Professor Of Neurology; Director Of The Rwjms Institute For Neurological Therapeutics; And Vice Chancellor For Faculty Development, Rutgers Biomedical And Health Sciences - Robert Wood Johnson Medical School
2021 · research · Target Advancement Program
Modulation of Epigenetic Regulator HDAC4 as a Parkinson’s Treatment
Richard Wade-Martins · University of Oxford
2021 · research · Improved Outcome Measures
Development of PD Biomarkers Using Focused Ultrasound-based Noninvasive Biopsy
Jerzy Olgierd Szablowski · Rice University
2021 · research · Research Grant
Development of Alpha-synuclein and Tau Imaging Agents
Chester A. Mathis · University of Pittsburgh
2021 · research · PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development
Characterization of PET Tracers for Alpha-synuclein and 4R Tau
Hans Ågren · Uppsala University
2021 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies
Testing the Neuroprotective Effects of Modulating Atp6v0a1
Rita Marie Cowell · University of Alabama at Birmingham
2021 · research · Priority Biology
Use of the Lipid BMP as a Surrogate Marker for LRRK2 and GCase Activity
Kalpana M. Merchant · Northwestern University
2021 · research · Research Grant
Changing Rhythms in Parkinson’s Disease: Development of Motor and Non-motor Markers of Progression Based on Continuous Daily Monitoring
Bastiaan R. Bloem · Radboud University Medical Center
2021 · research · Target Advancement Program
Sex-based Modulation of Neuromelanin-linked Parkinson’s Disease Pathology
Miquel Vila · Catalan Institution For Research And Advanced Studies, Vall D’hebron Research Institute
2021 · research · Therapeutic Pipeline Program
Identifying Small Molecule Binders of the LRRK2 WD Domain
Aled Edwards · Structural Genomics Consortium
2020 · research · Biosample Use Program
CSF RT-QuIC Alpha-Synuclein Amplification in LRRK2-Parkinson’s Disease
Maria Jose Martí · Neurosciences Clinic Institute Of The Hospital Clinic
2020 · research · Priority Biology
Structural Insights into Activated Intermediates of Parkin Continued
Kalle Gehring · McGill University
2020 · research · Target Advancement Program
Identification of ASC as a Disease-modifying Therapeutic Target in Parkinson’s Disease
Trent Martin Woodruff · The University of Queensland
2020 · research · Research Grant
Assessing Target Engagement for Terazosin
Jordan L. Schultz · University of Iowa
2020 · research · Therapeutic Pipeline Program
Adaptive Deep Brain Stimulation for Gait Retraining in Parkinson's Disease
Doris Du Wang · University of California, San Francisco
2020 · research · Priority Biology
Effects of LRRK2 Variants on GCase Activity in iPSC-derived Dopamine Neurons and Microglia
Ziv Gan-Or · McGill University
2020 · research · MJFF Funded Study
The Role of USP30 in Idiopathic Parkinson’s Disease
Emily Mangano Rocha · University of Pittsburgh
2020 · research · Research Grant
Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease
Christopher U. Missling · Anavex Life Sciences Corp.
2020 · research · Aligning Science Across Parkinson's
Role of PD-related Proteins as Drivers of Disease through Modulation of Innate and Adaptive Immunity
Michel Desjardins · Université de Montréal
2020 · research · Aligning Science Across Parkinson's
Mechanisms Overwhelming Protein and Organelle Quality Control in Parkinson’s Disease
J. Wade Harper · Harvard University
2020 · research · Research Grant
Discovery of Selective PET Imaging Agents for Tauopathies and Alpha-Synuclein
Neil Vasdev · Centre for Addiction and Mental Health
2020 · research · Therapeutic Pipeline Program
Phase II Trial of Bone Marrow-Derived Mesenchymal Stem Cells as a Disease-Modifying Therapy for Parkinson’s Disease
Mya Caryn Schiess · The University of Texas Health Science Center at Houston
2020 · research · Alpha-Synuclein Imaging
PET Imaging Probe Development for Alpha-synuclein
Changning Wang · Massachusetts General Hospital
2020 · research · Biosample Use Program
Single-molecule Detection of Oligomeric Synuclein in Body Fluids
Yann Gambin · European Molecular Biology Laboratory Australia